ELOUAN: Monocentric Retrospective Observational Study on Patients With Macular Degeneration
Study Details
Study Description
Brief Summary
Main Objective: The main objective of this retrospective observational study was to describe the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy Study) scale, for patients with exudative Age-Related Macular Degeneration (ARMD), treated with Lucentis, under real conditions of care, in terms of mean change of the Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| induction phase + intravitreal inj. Group of patients who received Lucentis ® with induction phase |
Other: intravitreal injections of Lucentis
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
|
| intravitreal inj. without induction Group of patients who received Lucentis ® without induction phase |
Other: intravitreal injections of Lucentis
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
|
| intravitreal inj. + monthly follow-up group of patients who were monthly monitored (+/- 1 week) |
Other: intravitreal injections of Lucentis
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
|
| intravitreal inj. + follow-up :> 1 month group of patients with Follow up visits intervals> 1 month (+/- 1 week) |
Other: intravitreal injections of Lucentis
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
|
| intravitreal inj +induction+ month. FU Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week) |
Other: intravitreal injections of Lucentis
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
|
| date Lucentis® 1st intravitreal Inj. Group of patients selected in accordance with the date of Lucentis® treatment start. |
Other: intravitreal injections of Lucentis
intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
|
Outcome Measures
Primary Outcome Measures
- Best Corrected Visual Acuity (BCVA), measured at 24 months (± 4 weeks). [measured at 24 months (± 4 weeks)]
Secondary Outcome Measures
- the mean change of the BCVA throughout the 24 months of follow-up (FU), [24 months of follow-up]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with exudative-subfove ARMD, regardless the neovessel type or the initial visual acuity; 2 - Patients treated in the department with intra vitreous injection of Lucentis ® during the study period (08/2011 and 02/2013); 3 - If both eyes are eligible, both will be analyzed;
Exclusion Criteria:
-
- Patients who received, for the studied eye, a treatment with a Vascular endothelial growth factor (VEGF) other than Lucentis ® in the three months preceding the start of the study. For those who received combination therapy, the nature of the treatment will be specified and taken into account in the subgroups for statistical analyzes;
-
- Patients with high myopia or neovessel not related to exudative-ARMD;
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hopital Saint Joseph | Marseille | France | 13008 |
Sponsors and Collaborators
- Hospital St. Joseph, Marseille, France
Investigators
- Study Chair: Maud RIGHINI, MD, HSJ
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ELOUAN HSJ 2014